These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3471432)

  • 1. An in vitro study of the interaction between cefotaxime and desacetylcefotaxime.
    Winstanley TG; Spencer RC
    Drugs Exp Clin Res; 1986; 12(12):967-71. PubMed ID: 3471432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime.
    Quintiliani R; Nightingale CH; Tilton R
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):63S-70S. PubMed ID: 6086220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
    Aldridge KE; Sanders CV; Marier RL
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):47S-53S. PubMed ID: 6086218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial activity of ceftizoxime against gram-negative strains.
    Debbia E; Soro O
    Chemioterapia; 1985 Apr; 4(2):166-9. PubMed ID: 3891115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
    Jenkins SG; Lewis JW
    Infection; 1995; 23(3):154-61. PubMed ID: 7499004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.
    Oizumi K; Hayashi I; Aonuma S; Konno K
    Drugs; 1988; 35 Suppl 2():57-61. PubMed ID: 3135170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL; Bergstrom R; Gibbons A
    Diagn Microbiol Infect Dis; 1989; 12(1):73-80. PubMed ID: 2653715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
    Jenkins SG
    Diagn Microbiol Infect Dis; 1989; 12(1):51-5. PubMed ID: 2714073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
    Neu HC
    Rev Infect Dis; 1982; 4 Suppl():S374-8. PubMed ID: 6294786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.
    Smith JA; Henry D; Ngui-Yen J; Castell A; Coderre S
    J Clin Microbiol; 1986 Jun; 23(6):1104-8. PubMed ID: 2872231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of ceftizoxime against aminoglycoside-resistant aerobic gram-negative bacilli.
    Gómez-Lus R; Rubio MC; García C; Gómez-Lus ML; Alejandre MC
    Drugs Exp Clin Res; 1987; 13(3):155-9. PubMed ID: 3497792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.
    Piédrola G; Galan I; Leyva A; Maroto MC
    Drugs; 1988; 35 Suppl 2():62-4. PubMed ID: 3135171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical laboratory approach for estimating effective administrative dose of ceftizoxime. Observation from MIC and ceftizoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1987 Feb; 40(2):331-9. PubMed ID: 3474430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.